Cosentyx vs Otezla
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Cosentyx | US Otezla | |
|---|---|---|
| Generic name | secukinumab | apremilast |
| Drug class | IL-17A Inhibitor (Biologic) | PDE4 Inhibitor |
| Treats | Plaque psoriasis, psoriatic arthritis, ankylosing spondylitis | Plaque psoriasis, psoriatic arthritis, Behçet's disease |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Novartis | Amgen |
| Year approved | 2015 | 2014 |
| FDA warning | Moderate warnings | No boxed warning |
| Est. TV ad spend | $160M | $110M |
| Common side effects | Respiratory infections, Inflammatory bowel disease, Fungal infections, Injection site reactions | Diarrhea, Nausea, Headache, Weight loss |
Frequently asked questions
Is Cosentyx or Otezla better?
Neither is universally "better." Cosentyx (secukinumab) and Otezla (apremilast) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Cosentyx and Otezla?
Cosentyx is a IL-17A Inhibitor (Biologic) made by Novartis, while Otezla is a PDE4 Inhibitor made by Amgen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Cosentyx has the larger estimated TV advertising budget of the two.